Asia prostate cancer study (A-CaP Study) launch symposium.
The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the course of 2 years. The A-CaP Study is scheduled to begin in 2016, when each participating country or region will begin registration of newly diagnosed prostate cancer patients and conduct prognosis investigations. From the data gathered, common research themes will be identified, such as comparisons among Asian countries of background factors in newly diagnosed prostate cancer patients. This is the first Asia-wide study of prostate cancer and has developed from single country research efforts in this field, including in Japan and Korea. The inaugural Board Meeting of A-CaP was held on December 11, 2015 at the Research Center for Advanced Science and Technology, The University of Tokyo, attended by representatives of all participating countries and regions, who signed a memorandum of understanding concerning registration for A-CaP. Following the Board Meeting an A-CaP Launch Symposium was held. The symposium was attended by representatives of countries and regions participating in A-CaP, who gave presentations. Presentations and a keynote address were also delivered by representatives of the University of California San Francisco, USA, and the Peter MacCallum Cancer Centre, Australia, who provided insight and experience on similar databases compiled in their respective countries.
Graduate School of Interdisciplinary Information Studies, The University of Tokyo, Japan.
Hideyuki
H
Akaza
Osaka Gyoumeikan Hospital, Japan.
Yoshihiko
Y
Hirao
Asan Medical Center, South Korea.
Choung-Soo
CS
Kim
Keio University School of Medicine, Japan.
Mototsugu
M
Oya
Hamamatsu University School of Medicine, Japan.
Seiichiro
S
Ozono
Fudan University Shanghai Cancer Center, China.
Dingwei
D
Ye
University of California San Francisco, United States.
Matthew
M
Cooperberg
Okayama University Hospital, Japan.
Shiro
S
Hinotsu
St. Mary's Hospital, The Catholic University of Korea, South Korea.
Ji Youl
JY
Lee
Beijing United Family Hospital and Clinics, China.
Gang
G
Zhu
Graduate School of Medical Science, Kanazawa University, Japan.
Mikio
M
Namiki
Juntendo University Graduate School of Medicine, Japan.
Shigeo
S
Horie
Yonsei University College of Medicine, South Korea.
Byung Ha
BH
Chung
National Taiwan University Hospital, Taiwan.
Chung-Hsin
CH
Chen
Division of Urology, The Chinese University of Hong Kong, Hong Kong.
Ng Chi
NC
Fai
Department of Urology, Airlangga University/Dr. Soetomo General Hospital, Surabaya, Indonesia.
Lukman
L
Hakim
National University Health System, Singapore.
Edmund
E
Chiong
Cardinal Santos Medical Center, The Philippines.
Jason
J
Letran
Faculty of Medicine, University of Indonesia, Indonesia.
Rainy
R
Umbas
Gunma University School of Medicine, Japan.
Kazuhiro
K
Suzuki
Osaka Medical Center for Cancer & Cardiovascular Diseases, Japan.
Kazuo
K
Nishimura
Faculty of Medicine, University of Malaya, Malaysia.
Teng Aik
TA
Ong
Faculty of Medicine, Chiang Mai University, Thailand.
Bannakij
B
Lojanapiwat
Kaohsiung Veterans General Hospital, Taiwan.
Tong-Lin
TL
Wu
Chungbuk National Medical University Hospital, South Korea.
Wun-Jae
WJ
Kim
Peter MacCallum Cancer Centre, Australia.
Declan
D
Murphy
Graduate School of Medicine, Kyoto University, Japan.
Osamu
O
Ogawa
University of California San Francisco, United States.
Peter
P
Carroll
Harasanshin Hospital, Japan.
Seiji
S
Naito
School of Medicine, Sapporo Medical University, Japan.
Taiji
T
Tsukamoto
Asian Cancer; Database; Prospective Study; Prostate Cancer
Prostate Int. 2014;2(2):50-69
26153555
Prostate Int. 2014 Sep;2(3):133-9
25325025
Chin J Cancer Res. 2015 Feb;27(1):2-12
25717220
Asian J Urol. 2014 Oct;1(1):15-29
29511634
Eur Urol. 2016 Jun;69(6):998-1012
26056070